Simple Summary This study analyzed patients with metastatic bladder cancer. A total of 108
patients received immunotherapy, but 11 had to stop their immunotherapy because of …

Introduction As most patients with metastatic urothelial carcinoma (mUC) will be treated with
immune checkpoint inhibitors (ICI), familiarity with their associated immune-related adverse …

Objectives: To examine patient and disease characteristics, toxicity, and clinical outcomes
for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune …

Abstract Introduction Immune checkpoint inhibitors (ICIs) have become one of the mainstays
of systemic therapy for advanced urothelial carcinoma (aUC). Increasingly ICIs are also …

Background In this study, we report real-world results from the 5-year follow-up data of
urothelial carcinoma patients treated with immune checkpoint blockade therapies (ICTs) …

There are few data on outcomes for patients with metastatic urothelial carcinoma (MUC) who
receive chemotherapy (CT) after progression on immune checkpoint inhibitors (ICIs). We …

Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for
metastatic urothelial cancer (mUC) after the failure of previous platinum-based …

Immune checkpoint inhibitors (ICIs) are active in metastatic urothelial carcinoma (MUC).
They have joined chemotherapy (CT) as a standard of care. Here, we investigate the activity …

Background Immune checkpoint inhibitors (ICIs) are used widely for treating metastatic
urothelial carcinoma (mUC). In practical settings, evidence is lacking on the efficacy of ICIs …

Background In advanced urothelial cancers (UC), immune checkpoint inhibitors (ICI) show
promise as a durable therapy. Immune-related adverse events (irAEs), a side effect of ICIs …